• Je něco špatně v tomto záznamu ?

Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors in patients with advanced malignant melanoma and non-small cell lung cancer

S. Borilova, P. Grell, I. Selingerova, L. Gescheidtova, M. Mlnarikova, O. Bilek, R. Lakomy, A. Poprach, J. Podhorec, I. Kiss, R. Vyzula, B. Vavrusakova, J. Nevrlka, L. Zdrazilova-Dubska

. 2024 ; 24 (1) : 1590. [pub] 20241230

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002958

Grantová podpora
00209805 Development of Research Organization MMCI
LX22NPO5102 National Institute for Cancer Research (Programme EXCELES)
NU21-03-00539 Ministry of Health of the Czech Republic
MUNI/A/1580/2023 European Union-Next Generation EU and by Specific University Research

BACKGROUND: Immune checkpoint inhibitors (ICIs), including those targeting PD-1, are currently used in a wide range of tumors, but only 20-40% of patients achieve clinical benefit. The objective of our study was to find predictive peripheral blood-based biomarkers for ICI treatment. METHODS: In 41 patients with advanced malignant melanoma (MM) and NSCLC treated with PD-1 inhibitors, we analyzed peripheral blood-based immune subsets by flow cytometry before treatment initialization and the second therapy dose. Specifically, we assessed basic blood differential count, overall T cells and their subgroups, B cells, and myeloid-derived suppressor cells (MDSC). In detail, CD4 + and CD8 + T cells were assessed according to their subtypes, such as central memory T cells (TCM), effector memory T cells (TEM), and naïve T cells (TN). Furthermore, we also evaluated the predictive value of CD28 and ICOS/CD278 co-expression on T cells. RESULTS: Patients who achieved disease control on ICIs had a significantly lower baseline proportion of CD4 + TEM (p = 0.013) and tended to have a higher baseline proportion of CD4 + TCM (p = 0.059). ICI therapy-induced increase in Treg count (p = 0.012) and the proportion of CD4 + TN (p = 0.008) and CD28 + ICOS- T cells (p = 0.012) was associated with disease control. Patients with a high baseline proportion of CD4 + TCM and a low baseline proportion of CD4 + TEM showed significantly longer PFS (p = 0.011, HR 2.6 and p ˂ 0.001, HR 0.23, respectively) and longer OS (p = 0.002, HR 3.75 and p ˂ 0.001, HR 0.15, respectively). Before the second dose, the high proportion of CD28 + ICOS- T cells after ICI therapy initiation was significantly associated with prolonged PFS (p = 0.017, HR 2.51) and OS (p = 0.030, HR 2.69). Also, a high Treg count after 2 weeks of ICI treatment was associated with significantly prolonged PFS (p = 0.016, HR 2.33). CONCLUSION: In summary, our findings suggest that CD4 + TEM and TCM baselines and an early increase in the Treg count induced by PD-1 inhibitors and the proportion of CD28 + ICOS- T cells may be useful in predicting the response in NSCLC and MM patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002958
003      
CZ-PrNML
005      
20250206103956.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-024-13351-x $2 doi
035    __
$a (PubMed)39736542
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Borilova, Simona $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors in patients with advanced malignant melanoma and non-small cell lung cancer / $c S. Borilova, P. Grell, I. Selingerova, L. Gescheidtova, M. Mlnarikova, O. Bilek, R. Lakomy, A. Poprach, J. Podhorec, I. Kiss, R. Vyzula, B. Vavrusakova, J. Nevrlka, L. Zdrazilova-Dubska
520    9_
$a BACKGROUND: Immune checkpoint inhibitors (ICIs), including those targeting PD-1, are currently used in a wide range of tumors, but only 20-40% of patients achieve clinical benefit. The objective of our study was to find predictive peripheral blood-based biomarkers for ICI treatment. METHODS: In 41 patients with advanced malignant melanoma (MM) and NSCLC treated with PD-1 inhibitors, we analyzed peripheral blood-based immune subsets by flow cytometry before treatment initialization and the second therapy dose. Specifically, we assessed basic blood differential count, overall T cells and their subgroups, B cells, and myeloid-derived suppressor cells (MDSC). In detail, CD4 + and CD8 + T cells were assessed according to their subtypes, such as central memory T cells (TCM), effector memory T cells (TEM), and naïve T cells (TN). Furthermore, we also evaluated the predictive value of CD28 and ICOS/CD278 co-expression on T cells. RESULTS: Patients who achieved disease control on ICIs had a significantly lower baseline proportion of CD4 + TEM (p = 0.013) and tended to have a higher baseline proportion of CD4 + TCM (p = 0.059). ICI therapy-induced increase in Treg count (p = 0.012) and the proportion of CD4 + TN (p = 0.008) and CD28 + ICOS- T cells (p = 0.012) was associated with disease control. Patients with a high baseline proportion of CD4 + TCM and a low baseline proportion of CD4 + TEM showed significantly longer PFS (p = 0.011, HR 2.6 and p ˂ 0.001, HR 0.23, respectively) and longer OS (p = 0.002, HR 3.75 and p ˂ 0.001, HR 0.15, respectively). Before the second dose, the high proportion of CD28 + ICOS- T cells after ICI therapy initiation was significantly associated with prolonged PFS (p = 0.017, HR 2.51) and OS (p = 0.030, HR 2.69). Also, a high Treg count after 2 weeks of ICI treatment was associated with significantly prolonged PFS (p = 0.016, HR 2.33). CONCLUSION: In summary, our findings suggest that CD4 + TEM and TCM baselines and an early increase in the Treg count induced by PD-1 inhibitors and the proportion of CD28 + ICOS- T cells may be useful in predicting the response in NSCLC and MM patients.
650    _2
$a lidé $7 D006801
650    12
$a melanom $x farmakoterapie $x imunologie $x krev $x patologie $7 D008545
650    _2
$a mužské pohlaví $7 D008297
650    12
$a inhibitory kontrolních bodů $x terapeutické užití $x farmakologie $7 D000082082
650    12
$a nemalobuněčný karcinom plic $x farmakoterapie $x imunologie $x krev $x patologie $7 D002289
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádory plic $x farmakoterapie $x imunologie $x krev $x patologie $7 D008175
650    _2
$a senioři $7 D000368
650    _2
$a dospělí $7 D000328
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antigeny CD279 $x antagonisté a inhibitory $7 D061026
650    _2
$a antigeny CD28 $7 D018106
650    _2
$a antigeny CD278 $x metabolismus $7 D060889
650    _2
$a CD8-pozitivní T-lymfocyty $x imunologie $x účinky léků $x metabolismus $7 D018414
655    _2
$a časopisecké články $7 D016428
700    1_
$a Grell, Peter $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. peter.grell@mou.cz $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic. peter.grell@mou.cz
700    1_
$a Selingerova, Iveta $u Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Gescheidtova, Lenka $u Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Mlnarikova, Marie $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Bilek, Ondrej $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Lakomy, Radek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Podhorec, Jan $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Vyzula, Rostislav $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Vavrusakova, Barbora $u Research Center for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Nevrlka, Jiri $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Laboratory Medicine, Department of Laboratory Methods, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic
700    1_
$a Zdrazilova-Dubska, Lenka $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Laboratory Medicine, Department of Laboratory Methods, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 24, č. 1 (2024), s. 1590
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39736542 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103952 $b ABA008
999    __
$a ok $b bmc $g 2263012 $s 1238965
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 24 $c 1 $d 1590 $e 20241230 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
GRA    __
$a 00209805 $p Development of Research Organization MMCI
GRA    __
$a LX22NPO5102 $p National Institute for Cancer Research (Programme EXCELES)
GRA    __
$a NU21-03-00539 $p Ministry of Health of the Czech Republic
GRA    __
$a MUNI/A/1580/2023 $p European Union-Next Generation EU and by Specific University Research
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace